{
  "VascularHealthFramework": {
    "Purpose": "Evidence-based vascular health recommendations derived from ReCOGnAIze research",
    "ResearchBasis": "Mohammed et al., 2025 - ReCOGnAIze app study on VCI detection",
    "KeyFindings": {
      "VCIPrevalence": "VCI accounts for 50-70% of all dementia globally",
      "UnderdiagnosisRate": "50-70% of VCI cases remain undiagnosed",
      "Treatability": "VCI responds well to intensive vascular risk factor management"
    },
    "VascularRiskFactors": {
      "Hypertension": {
        "PrevalenceInVCI": 0.373,
        "PrevalenceInNonVCI": 0.266,
        "ClinicalSignificance": "Major modifiable risk factor",
        "ThresholdForRisk": {
          "Stage1": "120-139 mmHg systolic",
          "Stage2": "140+ mmHg systolic"
        },
        "OptimalTarget": {
          "Value": "<120 mmHg systolic",
          "Evidence": "SPRINT MIND trial: intensive BP control significantly reduces cognitive impairment progression",
          "RiskReduction": "Intense BP control can delay dementia onset by ~5 years"
        },
        "Recommendations": [
          "Monitor blood pressure regularly (weekly for elevated)",
          "Engage in aerobic exercise (150 min/week moderate intensity)",
          "Reduce sodium intake to <2,300 mg/day",
          "Maintain DASH diet (Dietary Approaches to Stop Hypertension)",
          "Manage stress through meditation or yoga",
          "Limit alcohol consumption",
          "Maintain healthy weight (BMI 18.5-24.9)"
        ]
      },
      "Hyperlipidemia": {
        "PrevalenceInVCI": 0.60,
        "PrevalenceInNonVCI": 0.354,
        "StatisticalSignificance": "p=0.003 - Strongest discriminator between VCI and non-VCI",
        "EffectSize": "Cohen's d effect noted as significant",
        "Role": "60% of VCI patients have hyperlipidemia vs 35.4% without VCI",
        "OptimalTargets": {
          "TotalCholesterol": "<200 mg/dL",
          "LDL": "<100 mg/dL",
          "HDL": ">40 mg/dL (men), >50 mg/dL (women)",
          "Triglycerides": "<150 mg/dL"
        },
        "Recommendations": [
          "Annual lipid panel screening",
          "Increase soluble fiber intake (oats, beans, fruits)",
          "Choose lean proteins and fish rich in omega-3",
          "Eliminate trans fats and limit saturated fats",
          "Engage in 30 minutes of daily aerobic activity",
          "Maintain healthy weight",
          "Consider statin therapy if lifestyle changes insufficient"
        ]
      },
      "DiabetesMellitus": {
        "PrevalenceInVCI": 0.227,
        "PrevalenceInNonVCI": 0.19,
        "StatisticalSignificance": "p=0.234 (not statistically significant but elevated trend)",
        "ClinicalSignificance": "Elevated in VCI group, warrants management",
        "DiagnosticCriteria": {
          "Fasting": "≥126 mg/dL",
          "RandomBlood": "≥200 mg/dL with symptoms",
          "A1C": "≥6.5%"
        },
        "Recommendations": [
          "Regular A1C monitoring (target <7% for most, <8% for elderly)",
          "Blood glucose self-monitoring when on medications",
          "Maintain consistent carbohydrate intake timing",
          "Prioritize complex carbohydrates and high-fiber foods",
          "Engage in 150 minutes moderate-intensity aerobic exercise/week",
          "Resistance training 2-3 times weekly",
          "Maintain healthy weight (BMI reduction of 5-10% if overweight)",
          "Manage stress and ensure adequate sleep (7-8 hours)"
        ]
      }
    },
    "VascularCognitiveMarkers": {
      "ProcessingSpeed": {
        "Description": "Key VCI biomarker from ReCOGnAIze study",
        "SHAPImportance": 0.53,
        "MeasurementMethod": "Symbol Matching task - average response time",
        "ImpairmentIndicator": "Slowed processing and reduced efficiency",
        "ClinicalSignificance": "Hallmark of subcortical ischemic VCI",
        "MechanismInVCI": "Small vessel disease disrupts frontal-subcortical circuits"
      },
      "ExecutiveFunction": {
        "Description": "Higher-order cognitive processes affected in VCI",
        "PrevalenceInVCI": 0.82,
        "MeasurementMethod": "Trail Making Test adaptation",
        "Impairments": [
          "Difficulty with set-shifting",
          "Reduced cognitive flexibility",
          "Impaired task planning",
          "Slower execution of complex tasks",
          "Increased error rates on alternating tasks"
        ],
        "ClinicalSignificance": "Particularly vulnerable to frontal-subcortical circuit disruption"
      },
      "ImpulseControl": {
        "Description": "Ability to resist urges and inhibit inappropriate responses",
        "PrevalenceInVCI": 0.79,
        "MeasurementMethod": "Go/No-Go paradigm (Airplane Game)",
        "VCICharacteristic": "Significantly greater impairment in VCI vs non-VCI (p<0.001)",
        "BehavioralManifestation": "Impulse dyscontrol is significant behavioral manifestation",
        "Impairments": [
          "Difficulty inhibiting responses",
          "Impulsive behavior",
          "Poor sustained attention",
          "Increased false positives on go/no-go tasks",
          "Distractibility"
        ]
      }
    },
    "NeuroimagingMarkers": {
      "WhiteMatterHyperintensities": {
        "Description": "Key vascular pathology indicator",
        "MeasurementScale": "Modified Fazekas Score (0-12)",
        "Classification": {
          "Absent-Mild": "Score 0-4",
          "Moderate-Severe": "Score 5-12"
        },
        "VCIDefinition": "Moderate-to-high WMH (Fazekas 5-12) with cognitive impairment",
        "ClinicalSignificance": "Associated with VCI diagnosis"
      }
    },
    "ScreeningRecommendations": {
      "MoCALimitation": "Non-significant in detecting VCI; AUC=0.65",
      "ReCOGnAIzePerformance": "AUC=0.85 for VCI detection",
      "OptimalApproach": "Gamified tablet-based assessment targeting VCI-specific biomarkers",
      "ScreeningFrequency": {
        "HighRisk": "Annually if multiple vascular risk factors (HTN + HLD, or DM)",
        "ModerateRisk": "Every 2 years",
        "LowRisk": "Every 3-5 years over age 65"
      }
    },
    "InterventionTimeline": {
      "CriticalWindow": "MCI stage or earlier",
      "RiskConversion": "MCI individuals have 10-15% annual risk of conversion to dementia",
      "PotentialImpact": "5-year delay in dementia onset could reduce prevalence by ~50%",
      "CurrentlyAvailable": "Lifestyle interventions + intensive vascular risk factor management",
      "FutureDirections": "Emerging pharmacotherapies with improved safety profiles for VCI"
    },
    "DispropionateAffected": {
      "PopulationsAtHighestRisk": [
        "Asian populations",
        "African populations",
        "Hispanic populations"
      ],
      "RiskDrivers": [
        "Elevated hypertension rates",
        "High ischemic stroke burden",
        "Diabetes prevalence",
        "Sedentary lifestyles",
        "Genetic predispositions"
      ]
    }
  }
}
